Professor Anne Thomas

Anne Thomas and Martin Johnson

Professor of Cancer Therapeutics

Contact details

  • Tel: +44(0)116 258 7601
  • Email:
  • Office: Level 2, Osborne Building, Leicester Royal Infirmary

Personal details

Personal assistant: Linda Willis, Email:, Tel: 0116 258 7597

  • BM (Southampton) July 1991
  • MRCP (UK) March 1994
  • PhD (Nottingham) May 1999
  • FRCP (London) May 2005

My clinical interests include the management of patients with upper and lower gastrointestinal malignancies including GIST. I run a phase I trials clinic which accepts referrals from anywhere in the UK

I'm the Director of the Hope Against Cancer Clinical Trials Facility at the Leicester Royal Infirmary. This unit, opened in 2012, houses the research teams and provides the clinical environment where all patients receiving unlicensed drugs are treated in the Hope Facility. More than 100 clinical studies are currently being run in a wide range of cancer types. I'm also Clinical Lead for Research in the Academic Cancer Studies Department and Lead of the Leicester Experimental Cancer Medicine Centres (ECMC).

Academic distinctions and national profile

  • Board of Examiners for the Speciality Certificate Exam in Medical Oncology: Since 2009
  • Member of the East Midlands Regional NIHR Research for Patient Benefit Grant Awards Committee: 2011-2015
  • Clinical Specialist to NICE on behalf of the RCP/NCRI/RCR/ACP/JCCO on two single technology appraisals
  • Executive Committee of the British Association for Cancer Research: 2008 - 2010
  • Colorectal Clinical Study Group of the NCRI: Since 2014
  • Oesophago-gastric Subgroup of the Upper GI Clinical Study Group of the NCRI: Since 2009
  • Psychosocial Oncology Clinical Study Group of the NCRI: 2009-2011.
  • Chairman of the Advanced Disease Subgroup of the Colorectal Clinical Study Group of the NRCI: Since 2014


I have two major research interests:

  • The design and delivery of early phase clinical studies including chemoprevention strategies
  • Improving information exchange in oncology consultations

Design and delivery of early phase clinical studies

I have designed two clinical studies through the Astra Zeneca/NCRI Collaboration and the Astra Zeneca/ECMC Collaboration Initiative. The first, FOLFERA, was the inaugural study for the programme which has now closed to recruitment. Within the Chemoprevention group, I'm helping design clinical studies using dietary agents such as curcumin, in relevant doses. The studies are mainly in colorectal cancer and test strategies using curcumin with chemotherapy and as nanotherapy in patients at high risk of developing cancer.

Improving information exchange in oncology consultations

I lead a group ‘Better Consultations in Cancer Care’ which pulls together a multi-disciplinary team with a patient and carer group intimately involved in advising trial design. This is in collaboration with Dr Ged Murtagh, Imperial College. The group has developed a novel consultation aid which can be used by both the patient and doctor together to facilitate information exchange within an oncology consultation. This was through a grant from NIHR Research for Patient Benefit Programme. The consultation aid can be viewed here.


Selected publications

Book chapters

  1. Thomas AL ‘Chemotherapy and Hormonal Treatment’ In: Walter and Miller’s Textbook of Radiotherapy. 2012. 7th Edition, Elsevier (UK).
  2. Steward WP & Thomas AL ‘The Burden of Cancer’ In: The Molecular Biology of Cancer: A Bridge from Bench to Bedside. 2013. 2nd Edition, Ed Pelengaris and Khan. Blackwell Publishing, Oxford UK pg 43-66.
  3. Thomas AL, Morgan B & Steward WP ‘The Diagnosis of Cancer’ In: The Molecular Biology of Cancer: A Bridge from Bench to Bedside. 2013. 2nd Edition, Ed Pelengaris and Khan. Blackwell Publishing, Oxford UK pg 509-525.
  4. Thomas AL, Sage JP, Steward WP ‘Treatment of Cancer: Chemotherapy and Radiotherapy’ In: The Molecular Biology of Cancer: A Bridge from Bench to Bedside.  2013. 2nd Edition, Ed Pelengaris and Khan. Blackwell Publishing, Oxford UK pg 526-543.


Thomas AL and Walter H. 2013. Liver resection following FOLFOXIRI plus Bevacizumab: a detailed pathological review: Br J Cancer, June 25; 108 (12): 2417-8.


  1. Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Laurent D and Steward WP. 2005. Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PTK787/ZK 222584 (PTK/ZK) administered on a twice-daily basis in patients with advanced cancer.  Journal of Clinical Oncology 23(180: 4162-4171.
  2. Thomas AL, Bartel C, Trarbach T, Laurent D, Henry A, Poethig M, Wang J, Masson E, Steward W, Vanhoefer U, Wiedenmann B.  2007.  A phase 1B, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.  Annals of Oncology 18, 782-788.
  3. Dixon-Woods M, Angell E, Tarrant C & Thomas AL. 2008 What do research ethics committees say about applications to do cancer trials. Lancet Oncology 9: 700-701.
  4. Harrington C, Le Pla R, Jones GDD, Thomas AL & Farmer P 2010 Determination of cisplatin 1,2-Intrastrand guanine-guanine DNA adducts in human leucocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry. Chem. Res. Toxicol 23(8):1313–1321.
  5. Zayed A, Jones GDD, Reid HJ, Shoeib T, Taylor SE, Thomas AL, Wood JP, Sharp BL 2011 Speciation of oxaliplatin adducts with DNA nucleotides.  Metallomics 3(10): 991-1000
  6. Murtagh G, Furber L, Thomas AL. 2013.  Patient-initiated questions: How can doctors encourage them and improve the consultation process?  A qualitative study.  BMJ Open Oct 16;3 (10): e003112.
  7. Furber L, Murtagh G, Bonas SA, Bankart JG, Thomas AL.  2014.  Improving consultations in oncology: the development of a novel consultation aid.  British Journal of Cancer, Feb 18 110: 1101-1109.
  8. Rodon J, Tawbi HA, Thomas AL, Stoller R, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingham D, Shou Y, Moles MA, Yang L, Granvil C, Hurgh E, Rose KL, Amakye DD, Dummer R, Mita AC. 2014. A Phase 1 mulitcentre, open label, first-in-human, dose escalation study of the oral hedgehog inhibitor Sonidegib (LDE225) in patients with advanced solid tumours.  Clinical Cancer Research, Feb 12 (epub ahead of print).
  9. Price TJ, Peeters M, Kim TW, Li J, Carscinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Zhang K, Murugappan S, Sidhu R. 2014.  Panitumumab versus Cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open label, non-inferiority phase 3 study.  The Lancet Oncology 15(6) 569-579.
  10. Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas A, Jiang Y et al.  2014.  Rilotumamub in combination with Epirubicin, cisplatin and capecitabine as first-line treatment for gastric or oesphagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.  The Lancet Oncology, June 23.



  • PhD Mr Amar Eltweri
    Evaluating the role of omegaven in patients with oesophago-gastric cancer receiving chemotherapy. Academic supervisor and Clinical Supervisor – Mr D Bowrey
  • Academic Clinical Fellow – Dr Sameena Khan
    Investigating nanogas as a potential druggable target in colorectal stem - like cells using curcumin as a probe compound
  • Clinical Research Fellow Dr Mark Openshaw
    Cancer patient stratification by next generation sequencing of circulating DNA
  • Clinical Research Felllow – Dr Meera Chauhan
    Investigating Asprin and Ticagrelor for the prevention of tumour cell-induced platelet aggregation


Share this page:


Powerful pre-clinical platform for anti-cancer drug and biomarker discovery

Pre-clinical models that can accurately predict outcomes in the clinic are much sort after in the field of cancer drug discovery and development.  Read about how patient derived explants offer many advantages and are the powerful model of choice. A copy of the review, published in the British Journal of Cancer, is available by clicking this link: PDE Platform


SEND Study Success

Congratulations to Chris Avery, who with collaborating colleagues published findings of the SEND study, a multi-centre randomised trial using two different surgical protocols for mouth cancer treatment.  A nationwide first for this type of trial, using real-world data.  The paper, published in the British Journal of Cancer, is available by clicking this link: SEND Paper


Centre Health and Wellbeing Group
Join up for a walk on the park Friday lunchtime - details here.

More information from Jenny McNair

Contact Details

Leicester Cancer Research Centre
Robert Kilpatrick Clinical Sciences Building
University of Leicester
Leicester Royal Infirmary
Leicester LE2 7LX

T: +44 (0) 116 252 3170

(Please note this email address should not be used for clinical referrals or patient correspondence)

Maps and Directions

Sat Nav users: 


AccessAble logo

The University of Leicester is committed to equal access to our facilities. DisabledGo has a detailed accessibility guide for the Robert Kilpatrick Clinical Sciences Building.